Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

  • Awaiting development
  • GID-TA11758
  • Expected publication date: TBC

Register as a stakeholder

To appraise the clinical and cost effectiveness of Pelacarsen within its marketing authorisation for treating hyperlipoproteinemia ID6559